



Kentucky Medicaid Drug Management Review Advisory Board (DMRAB) Meeting



Tina Hawkins, PharmD
Clinical Program Manager
August 12, 2010

Agenda



- Welcome
- Approval of the May 13, 2010 Meeting Minutes
- Chair/Vice Chair Elections
- Speaker Policy
- Old Business
 - Suboxone®/Subutex®
 - Therapies for ADHD
 - Atypical Antipsychotics
- New Business
 - Population Statistics
 - Utilization Data
 - ProDUR
 - RetroDUR
 - Future DUR Activities
- Adjournment


DMRAB Interaction with PTAC

Task	DMRAB	PTAC
Review Utilization Data and make recommendations to DMS regarding specific drugs or drug classes which need prior authorization criteria and limitations	√	
Review clinical data and make recommendations to DMS regarding specific prior authorization criteria and limitations	√	√
Recommend RetroDUR activities and specific criteria for DMS	√	
Make recommendations for PDL placement of drugs within a given drug class along with prior authorization criteria and limitations		√

Old Business


- Utilization of Suboxone[®]/Subutex[®]
- Utilization of Therapies for ADHD
- Atypical Antipsychotics
 - Utilization by Age
 - Utilization by Drug
 - Utilization by Diagnosis
 - Utilization by Antidiabetic Agents

Suboxone[®]/Subutex[®] Utilization




The PA requirements started on 2/1/2010

Suboxone[®]/Subutex[®] Utilization



The PA requirements started on 2/1/2010

Suboxone[®]/Subutex[®] Utilization



The PA requirements started on 2/1/2010

Suboxone[®]/Subutex[®] Utilization




Medical Expense	October 2009-June 2010			October 2008-June 2009		
	Paid Amount	Patient Count	% Utilization	Paid Amount	Patient Count	% Utilization
Inpatient Hospital	\$432,558	73	17%	\$411,563	71	17%
Mental Hospital	\$330,560	291	69%	\$2,545	2	0%
Outpatient Hospital	\$927	2	0%	\$345,952	311	73%
Primary Care	\$69,769	134	32%	\$74,347	143	34%
CMHC	\$26,957	54	13%	\$16,700	45	11%
Independent Lab	\$565,011	305	72%	\$72,429	152	36%
Non Emergent Transportation	\$61	1	0%	\$985	9	2%
Pharmacy	\$1,526,118	424	100%	\$413,043	380	90%
Physician	\$358,044	361	85%	\$314,273	347	87%
Psychiatry	\$78,201	13	3%	\$83,871	12	3%


ADHD Drugs

- Utilization by Age
- Utilization by Payment Amount
- Utilization by Drug
- Utilization by Diagnosis


Utilization by Age




Utilization by Payment Amount




Utilization by Drug <4 Years



Utilization by Drug 4-8 Years




Utilization by Drug 9-12 Years




3 Provigil[®] claims

Utilization by Drug 13-19 Years




25 Provigil[®] claims and 5 Nuvigil[®] claims.

Utilization by Drug >19 Years




161 claims for Provigil[®] and 34 claims for Nuvigil[®]


Utilization by Diagnosis <4 Years




Utilization by Diagnosis 4-8 Years




Utilization by Diagnosis 9-12 Years



Utilization by Diagnosis 13-19 Years




Utilization by Diagnosis >19 Years




Atypical Antipsychotics

- Utilization by Age
- Utilization by Payment Amount
- Utilization by Drug
- Utilization by Diagnosis
- Utilization of Multiple Atypical Antipsychotics
- Utilization with Antidiabetic Agents


Utilization by Age




Utilization by Payment Amount




Utilization by Drug <4 Years




Utilization by Drug 4-8 Years




Utilization by Drug 9-12 Years




Utilization by Drug 13-19 Years




Utilization by Drug >19 Years




Utilization by Diagnosis <4 Years




Utilization by Diagnosis 4-8 Years




Utilization by Diagnosis 9-12 Years




Utilization by Diagnosis 13-19 Years




Utilization by Diagnosis >19 Years




Utilization of Multiple Atypicals Total Population




Utilization of Multiple Atypicals <4 Years




Utilization of Multiple Atypicals 4-8 Years




Utilization of Multiple Atypicals 9-12 Years




Utilization of Multiple Atypicals 13-19 Years



Utilization of Multiple Atypicals >19 Years



Utilization with Antidiabetic Drugs



Pharmacy Data

- Population Statistics
- Utilization Data
 - Total Population
 - Adult Population (age 19 and above)
 - Child Population (ages 0 through 18)
- Utilization by Disease States
 - Total Population
 - Adult Population (age 19 and above)
 - Child Population (ages 0 through 18)

Population

	2Q2010	2Q2009
Non-Dual Children (<19)	339,325	317,468
Non-Dual Adults (≥19) with Rx Limit	156,890	171,085
Dual Eligible Children	160	219
Dual Eligible Adults	87,441	75,703
Total Medicaid Population	583,816	564,473
Ave Pharmacy Utilizing Members per month < 19 (Children)	106,434	101,757
Ave Pharmacy Utilizing Members per month ≥19 (Adults)	134,415	133,125

Utilizing Members

	2Q2010	2Q2009
# Utilizing Members / Month	240,652	234,830
# Prescriptions / Month	914,810	885,894
Total Amount Paid / Month	\$47,788,291	\$46,144,567
Average # Rxs / Utilizing Member / Month	3.8	3.77
Average Amount Paid / Claim	\$52.25	\$52.08
Average Amount Paid / Utilizing Member	\$199.65	\$196.56
Average Amount Paid / Eligible Member	\$81.86	\$81.75

Average Prescription Payment

	Percent of Total Prescriptions		Average Rx Payment	
	2Q2010	2Q2009	2Q2010	2Q2009
Single Source Brand	20.34%	20.03%	\$170.64	\$162.63
Multi-Source Brand	5.64%	7.32%	\$89.89	\$96.93
Generic	74.03%	72.64%	\$16.79	\$17.06

Utilization Data

Total Population

Top 10 Therapeutic Classes By Claim Volume

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	Narcotic Analgesics	157,059	1	155,272
2	Anticonvulsants	147,633	2	139,448
3	2 nd Generation Antihistamines	113,114	3	98,664
4	Anti-Anxiety Drugs	92,702	4	89,822
5	PPIs	87,991	5	86,062
6	NSAIDs-COX Inhibitor Type	81,632	6	78,114
7	Penicillins	75,386	7	75,155
8	SSRIs	71,711	8	70,021
9	ADHD Drugs	70,444	11	66,006
10	1 st Generation Antihistamines	69,411	10	69,386

Top 10 Therapeutic Classes By Payment Amount

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Atypical Antipsychotics	\$17,062,406	1	\$15,967,847
2	ADHD Drugs	\$9,889,846	2	\$8,770,880
3	Narcotic Analgesics	\$7,621,561	5	\$6,408,626
4	PPIs	\$7,586,650	4	\$6,494,583
5	Anticonvulsants	\$7,294,209	3	\$8,702,723
6	Leukotriene Receptor Antagonists	\$4,471,770	6	\$3,832,301
7	Insulins	\$4,345,440	7	\$3,745,559
8	Beta-Adrenergic/ICS Combos	\$3,999,477	8	\$3,520,639
9	Statins	\$3,311,392	9	\$2,902,693
10	Beta-Adrenergic Agents	\$2,823,085	10	\$2,745,517

Top 10 Drugs By Claim Volume

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	hydrocodone/APAP	82,050	1	79,981
2	loratadine	66,201	2	63,075
3	Prilosec® OTC	52,392	3	56,729
4	amoxicillin	52,260	4	49,745
5	clonazepam	47,444	5	45,993
6	ibuprofen	42,194	7	39,894
7	azithromycin	41,688	6	44,101
8	Singulair®	36,648	9	33,742
9	lisinopril	36,560	8	33,993
10	gabapentin	33,420	14	27,033

Top 10 Drugs By Payment Amount

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Abilify®	\$5,186,638	1	\$4,833,290
2	Singulair®	\$4,433,046	3	\$3,789,656
3	Seroquel®	\$4,222,097	2	\$4,125,082
4	Nexium®	\$4,140,845	5	\$2,637,770
5	Crestor®	\$2,808,465	6	\$2,412,093
6	Advair Diskus®	\$2,704,111	4	\$2,667,114
7	Suboxone®	\$2,677,139	10	\$2,059,965
8	Concerta®	\$2,406,304	11	\$2,043,432
9	Adderall XR®	\$2,350,663	7	\$2,366,813
10	Zyprexa®	\$2,327,674	8	\$2,185,613

Utilization Data

Adult Population (Ages \geq 19)

Top 10 Therapeutic Classes By Claim Volume

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	Narcotic Analgesics	146,942	1	144,144
2	Anticonvulsants	128,261	2	120,450
3	Anti-Anxiety Drugs	91,459	3	88,236
4	PPIs	78,191	4	77,130
5	SSRIs	59,842	5	58,875
6	NSAIDs	56,976	6	54,785
7	2 nd Gen Antihistamines	54,031	8	50,430
8	Analgesic/antipyretics, Salicylates	52,400	7	54,444
9	Statins	51,128	10	44,874
10	Laxatives and Cathartics	50,054	9	49,469

Top 10 Therapeutic Classes By Payment Amount

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Atypical Antipsychotics	\$12,037,105	1	\$10,790,358
2	Narcotic Analgesics	\$7,503,644	3	\$6,261,829
3	PPIs	\$6,556,291	4	\$5,605,794
4	Anticonvulsants	\$5,521,179	2	\$6,690,048
5	Insulins	\$3,728,862	5	\$3,219,728
6	Statins	\$3,296,662	6	\$2,891,129
7	Beta Adrenergic/ICS Combos	\$3,149,161	7	\$2,742,584
8	Platelet Inhibitors	\$2,200,655	8	\$1,962,047
9	Lipotropics	\$2,136,802	10	\$1,808,773
10	SNRIs	\$1,666,886	14	\$1,396,686

Top 10 Drugs By Claim Volume

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	hydrocodone/APAP	74,899	1	72,394
2	Prilosec OTC [®]	48,313	2	52,670
3	clonazepam	46,147	3	44,684
4	loratadine	39,168	4	38,323
5	lisinopril	35,604	6	33,128
6	gabapentin	32,861	9	26,569
7	alprazolam	32,806	7	29,170
8	aspirin EC	31,904	5	33,336
9	diazepam	27,462	8	26,602
10	levothyroxine	24,133	12	22,675

Top 10 Drugs By Payment Amount

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Nexium®	\$3,841,942	2	\$2,454,018
2	Seroquel®	\$3,338,617	1	\$3,188,554
3	Crestor®	\$2,796,271	3	\$2,403,031
4	Abilify®	\$2,655,085	4	\$2,344,562
5	Suboxone®	\$2,648,293	6	\$2,032,390
6	Advair® Diskus	\$2,222,458	5	\$2,163,103
7	Zyprexa®	\$2,118,330	7	\$1,978,514
8	Plavix®	\$2,083,263	8	\$1,879,193
9	Lyrica®	\$1,602,081	9	\$1,712,518
10	Actos®	\$1,419,754	13	\$1,387,717

Utilization Data

Child Population (Ages 0 through 18)

Top 10 Therapeutic Classes By Claim Volume

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	ADHD Drugs	65,779	1	61,349
2	2 nd Generation Antihistamines	59,091	3	48,015
3	Penicillins	56,558	2	55,369
4	Glucocorticoids	31,658	6	28,388
5	Macrolides	30,088	4	31,808
6	Beta Adrenergic Agents	29,852	5	28,852
7	Leukotriene Receptor Antagonists	25,187	10	22,481
8	NSAIDs	24,513	9	23,200
9	1 st Generation Antihistamines	24,380	7	23,994
10	Atypical Antipsychotics	21,261	11	21,355

Top 10 Therapeutic Classes By Payment Amount

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	ADHD Drugs	\$9,222,617	1	\$8,166,142
2	Atypical Antipsychotics	\$5,017,919	2	\$5,147,692
3	Leukotriene Receptor Antagonists	\$3,042,224	3	\$2,521,050
4	Glucocorticoids	\$2,088,817	5	\$1,976,740
5	Anticonvulsants	\$1,788,005	4	\$1,998,567
6	Intranasal Steroids	\$1,381,475	7	\$1,142,675
7	Beta Adrenergic Agents	\$1,278,582	6	\$1,239,438
8	Growth Hormones	\$1,207,593	8	\$1,082,295
9	Antihemophilic Factors	\$1,041,889	9	\$1,007,397
10	PPIs	\$1,026,407	13	\$882,535

Top 10 Drugs By Claim Volume

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	amoxicillin	41,294	1	38,743
2	azithromycin	28,442	2	29,790
3	loratadine	27,071	3	24,651
4	Singulair®	25,173	4	22,465
5	cetirizine	22,948	6	15,806
6	ibuprofen	19,323	5	17,906
7	Concerta®	14,807	7	14,272
8	cefdinir	14,747	8	13,869
9	clonidine	14,343	9	13,362
10	Vyvanse®	13,729	13	11,143

Top 10 Drugs By Payment Amount

2Q2010			2Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Singulair®	\$3,040,926	1	\$2,519,548
2	Abilify®	\$2,530,544	2	\$2,484,464
3	Concerta®	\$2,350,233	4	\$1,990,602
4	Adderall® XR	\$2,169,378	3	\$2,230,101
5	Vyvanse®	\$1,804,276	5	\$1,419,476
6	Nasonex®	\$1,076,009	6	\$1,051,620
7	Strattera®	\$1,006,851	7	\$981,601
8	budesonide	\$942,416	24	\$324,514
9	Focalin XR®	\$896,327	12	\$747,174
10	Seroquel®	\$882,958	8	\$923,578

Utilization by Disease States

Total
Population

Disease States By Claim Volume

	2Q2010		2Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Behavioral Health	98,676	360,394	95,504	347,849
GI	83,966	223,336	80,925	217,253
HTN	55,060	212,176	52,576	205,320
Diabetes	18,748	74,532	18,013	71,951
Cancer	4,949	9,188	4,612	8,858
HIV	198	1,026	203	1,009

Disease States By Payment Amount

Disease	Payment Amount 2Q2010	Payment Amount 2Q2009
Behavioral Health	\$31,452,597	\$29,478,088
GI	\$10,299,335	\$9,017,070
Diabetes	\$7,559,853	\$6,752,619
HTN	\$4,098,362	\$4,128,450
Cancer	\$2,641,035	\$2,204,287
HIV	\$813,013	\$773,506

Utilization Data

Adult Population (Ages \geq 19)

Disease States By Claim Volume

	2Q2010		2Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Behavioral Health	67,023	248,075	65,400	241,082
GI	63,066	187,645	62,598	185,923
HTN	45,410	188,501	43,717	183,676
Diabetes	17,183	69,666	16,632	67,744
Cancer	3,922	7,803	3,777	7,710
HIV	185	963	193	954

Disease States By Payment Amount

Disease	Payment Amount 2Q2010	Payment Amount 2Q2009
Behavioral Health	\$16,850,637	\$15,714,212
GI	\$8,494,198	\$7,579,665
Diabetes	\$6,869,700	\$6,182,814
HTN	\$3,726,468	\$3,810,010
Cancer	\$2,506,219	\$2,100,469
HIV	\$776,944	\$742,330

Utilization Data

Child Population (Ages 0 through 18)

Disease States By Claim Volume

	2Q2010		2Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Behavioral Health	31,653	112,319	30,104	106,767
GI	20,900	35,691	18,327	31,330
HTN	9,650	23,675	8,859	21,644
Diabetes	1,565	4,866	1,381	4,207
Cancer	1,027	1,385	835	1,148
HIV	13	63	10	55

Disease States By Payment Amount

Disease	Payment Amount 2Q2010	Payment Amount 2Q2009
Behavioral Health	\$14,601,960	\$13,763,876
GI	\$1,805,137	\$1,437,405
Diabetes	\$690,153	\$569,805
HTN	\$371,894	\$318,440
Cancer	\$134,816	\$103,817
HIV	\$36,069	\$31,177

Prospective Drug Utilization Review (ProDUR)

Edit Definitions

- **ProDUR Edit** – A computer system review of the member’s medication profile to identify potential drug therapy problems prior to dispensing the medication. Examples would include but not limited to:
 - Therapeutic Duplication (TD), Early Refill (ER), Max Dose, Drug to Gender, Drug to Drug, Drug to Inferred Disease, Geriatric and Pediatric Warnings
 - **Hard Edit** – These edits will cause the claim to deny at the point of sale (POS)
 - **Soft Edit** – These edits will cause an alert or warning message to be returned to the dispensing pharmacist to inform them of a potential problem. The pharmacist can bypass this message to process the claim after further evaluation and/or consultation with the patient or prescriber.

Edits Currently in POS System

ProDUR Conflict Type	Deny or Message Only	Provider Level Override or PA Required
Drug-to-Drug Interaction (DD)	Deny SL1	PA
Early Refill (ER) 80% tolerance	Deny	Provider PA CII
Therapeutic Duplication (TD)	Deny	Provider PA-Stimulants
Duplicate Ingredient (ID)	Deny	Provider
Min/Max Daily Dose (LD, HD)	Message	N/A

ProDUR Summary

	2Q2010	2Q2009
HD, LD	539,109	458,331
DD	952,560	860,777
TD	1,119,862	1,176,905
ID	451,351	418,629
ER	240,027	218,325
Total Claims with ProDUR Alerts	1,814,437	1,579,954
Total Claims	2,741,770	2,657,490
% of Claims with ProDUR Alerts	66.2%	59.4%
% of Claims with ProDUR Alerts NOT filled.	15.9%	16.9%

Review of Retrospective Drug Utilization Review (RetroDUR) Activities

RetroDUR Activities

February 2010 Claims

- Non-Compliance with ICS \leq 18 years old (\geq 15 days late for a refill)
 - 176 Recipients identified for intervention
 - 180 Prescribers lettered
- Responses returned:
 - 44.4% response rate
 - Responses with approval ratings:
 - Very Useful = 15%
 - Useful = 28%
 - Somewhat Useful = 5%
 - Neutral = 19%
 - Not Useful = 13%

RetroDUR Activities



March 2010 Claims

- Non-Compliance with ICS > 18 years old (≥ 15 days late for a refill)
 - 218 Recipients chosen for intervention
 - 222 Prescribers lettered
- Responses returned:
 - 18.5% response rate
 - Responses with approval ratings:
 - Very Useful = 32%
 - Useful = 46%
 - Somewhat Useful = 5%
 - Neutral = 12%
 - Not Useful = 17%

Ideas for Future DUR Activities

- Non compliance with Atypical Antipsychotics
- No metabolic monitoring in patients on Atypical Antipsychotics
- Utilization of Seroquel[®] for off label indications such as sleep
- Medications that increase the risk of falls in elderly
- APAP with other meds which may have hepatotoxic effects
- Non-compliance with statins after MI
- Non-compliance with cardiovascular drugs.



Kentucky Medicaid Drug Management Review Advisory Board (DMRAB) Meeting

Next Meetings:

November 4, 2010

February 10, 2010

Tina Hawkins, PharmD
Clinical Program Manager
August 12, 2010